Literature DB >> 11709090

Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients.

L Martín-Carbonero1, V Soriano, E Valencia, J García-Samaniego, M López, J González-Lahoz.   

Abstract

To assess the impact of chronic viral liver disease (CVLD) on hospital admissions and death in HIV-infected patients since the introduction of highly active antiretroviral therapy, all hospital charts, from January 1996 to December 2000, in a large HIV/AIDS reference center in Madrid were reviewed. Discharge diagnosis, complications during the inpatient period, and number and causes of death were recorded. A total of 1334 hospital admissions involving 875 HIV-infected individuals was recorded. Up to 82% of them were either active or former intravenous drug users. Overall, 158 (11.8%) were admitted because of complications of CVLD, or developed complications of CVLD during their admission for another reason. The absolute number and proportion of admissions caused by CVLD increased over time, from 9.4% (31 of 330) in 1996 to 16% (46 of 287) in 2000 (p < 0.05). Likewise, the total number and proportion of deaths due to CVLD increased from 9.3% (5 of 54) in 1996 to 45% (9 of 20) in 2000 (p < 0.05). Chronic hepatitis C was the only etiology in nearly three-quarters of patients who were admitted or died of CVLD. In conclusion, the proportion of hospital admissions caused by liver failure in HIV-infected patients has increased in the last 5 years, accounting for 16% of cases in 2000. End-stage liver disease currently represents 45% of causes of in-hospital death among HIV-infected individuals. Therefore, strategies to prevent infection by hepatitis viruses (hepatitis B vaccine) and specific treatment (interferon plus ribavirin for hepatitis C virus) should be encouraged among HIV-infected persons.

Entities:  

Mesh:

Year:  2001        PMID: 11709090     DOI: 10.1089/08892220152644160

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  27 in total

1.  Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosis.

Authors:  José Moltó; Marta Valle; Asunción Blanco; Eugenia Negredo; Meritxell DelaVarga; Cristina Miranda; José Miranda; Pere Domingo; Josep Vilaró; Cristina Tural; Joan Costa; Manuel José Barbanoj; Bonaventura Clotet
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Management of Hepatitis C in HIV-infected Patients.

Authors:  Benigno Rodriguez; David A Bobak
Journal:  Curr Infect Dis Rep       Date:  2005-03       Impact factor: 3.725

3.  Factors associated with seronegative chronic hepatitis C virus infection in HIV infection.

Authors:  Gabriel Chamie; Maurizio Bonacini; David R Bangsberg; Jack T Stapleton; Christopher Hall; E Turner Overton; Rebecca Scherzer; Phyllis C Tien
Journal:  Clin Infect Dis       Date:  2007-01-10       Impact factor: 9.079

4.  The impact of HIV/HCV co-infection on health care utilization and disability: results of the ACTG Longitudinal Linked Randomized Trials (ALLRT) Cohort.

Authors:  B P Linas; B Wang; M Smurzynski; E Losina; R J Bosch; B R Schackman; J Rong; P E Sax; R P Walensky; J Schouten; K A Freedberg
Journal:  J Viral Hepat       Date:  2010-06-09       Impact factor: 3.728

5.  Trends and causes of hospitalizations among HIV-infected persons during the late HAART era: what is the impact of CD4 counts and HAART use?

Authors:  Nancy F Crum-Cianflone; Greg Grandits; Sara Echols; Anuradha Ganesan; Michael Landrum; Amy Weintrob; Robert Barthel; Brian Agan
Journal:  J Acquir Immune Defic Syndr       Date:  2010-07       Impact factor: 3.731

Review 6.  Management of hepatitis B in patients coinfected with the human immunodeficiency virus.

Authors:  R Lessells; C Leen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2004-04-27       Impact factor: 3.267

Review 7.  Management of chronic hepatitis C in patients co-infected with HIV: focus on safety considerations.

Authors:  Miriam Romero; Mayte Pérez-Olmeda; Javier García-Samaniego; Vicente Soriano
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 8.  Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Authors:  Vincent Lo Re; Jay R Kostman; Valerianna K Amorosa
Journal:  Clin Liver Dis       Date:  2008-08       Impact factor: 6.126

9.  Significance of blood analysis in hemophiliacs co-infected with human immunodeficiency virus and hepatitis viruses.

Authors:  Fang Shen; Qin Huang; Hong-Qing Sun; Reena Ghildyal
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

10.  Efficacy and safety of atazanavir in patients with end-stage liver disease.

Authors:  G Guaraldi; S Cocchi; A Motta; S Ciaffi; M Codeluppi; S Bonora; F Di Benedetto; M Masetti; M Floridia; S Baroncelli; D Pinetti; A Bertolini; G E Gerunda; R Esposito
Journal:  Infection       Date:  2009-05-26       Impact factor: 3.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.